These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Glaucoma: Focus on mitochondria in relation to pathogenesis and neuroprotection. Osborne NN; Núñez-Álvarez C; Joglar B; Del Olmo-Aguado S Eur J Pharmacol; 2016 Sep; 787():127-33. PubMed ID: 27090928 [TBL] [Abstract][Full Text] [Related]
9. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Fu QL; Li X; Yip HK; Shao Z; Wu W; Mi S; So KF Neuroscience; 2009 Aug; 162(2):375-82. PubMed ID: 19422885 [TBL] [Abstract][Full Text] [Related]
10. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Foxton RH; Finkelstein A; Vijay S; Dahlmann-Noor A; Khaw PT; Morgan JE; Shima DT; Ng YS Am J Pathol; 2013 Apr; 182(4):1379-90. PubMed ID: 23416159 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Hains BC; Waxman SG Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotection: is it already applicable to glaucoma therapy? Ritch R Curr Opin Ophthalmol; 2000 Apr; 11(2):78-84. PubMed ID: 10848224 [TBL] [Abstract][Full Text] [Related]
14. The potential of neuroprotection in glaucoma treatment. Osborne NN; Chidlow G; Nash MS; Wood JP Curr Opin Ophthalmol; 1999 Apr; 10(2):82-92. PubMed ID: 10537768 [TBL] [Abstract][Full Text] [Related]
15. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Osborne NN Acta Ophthalmol; 2009 Jun; 87(4):450-4. PubMed ID: 19141144 [TBL] [Abstract][Full Text] [Related]
16. In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders? Haefliger IO; Fleischhauer JC; Flammer J Eye (Lond); 2000 Jun; 14 ( Pt 3B)():464-72. PubMed ID: 11026975 [TBL] [Abstract][Full Text] [Related]
17. Molecular and cell-based approaches for neuroprotection in glaucoma. Lebrun-Julien F; Di Polo A Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011 [TBL] [Abstract][Full Text] [Related]
18. Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper. Tamm ER; Schmetterer L; Grehn F Cell Tissue Res; 2013 Aug; 353(2):347-54. PubMed ID: 23712457 [TBL] [Abstract][Full Text] [Related]
19. History of neuroprotection and rationale as a therapy for glaucoma. Levin LA; Peeples P Am J Manag Care; 2008 Feb; 14(1 Suppl):S11-4. PubMed ID: 18284310 [TBL] [Abstract][Full Text] [Related]